FDA improperly denied Ranbaxy, Ivax rights to exclusivity

Share this article:
A federal judge ruled the FDA improperly denied generic drugmakers Ranbaxy and Ivax rights to 180 days of marketing exclusivity for generic forms of Merck's cholesterol-lowering drug Zocor (simvastatin). He threw out the FDA's decision to grant Merck's request to delist two patents.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.